| Category | Functional Skincare |
| Founded | 2014 |
| Headquarters | Shenzhen |
| Listing | Private; parent reported to be in IPO process (C2CC, Apr 2026) |
| Latest revenue | No audited financials disclosed |
| Hero SKUs | Retinol Night Cream / Glow Toner |
Brand History
HBN was founded in 2014 under Shenzhen Hujia Technology. After trying several categories, its turning point was a bet on retinol: China's anti-aging market was dominated by international peptides and pro-xylane, and domestic brands avoided retinol because of irritation and formulation difficulty. HBN used encapsulation and sustained release to reduce irritation, launched a retinol night cream, and packaged 'morning C, night A' into an executable routine.
To make the ingredient story credible, HBN invested in third-party efficacy testing, published clinical and human-efficacy data, and involved dermatologists in content. From 2021 to 2023 it scaled fast on Douyin, with the Glow Toner and retinol cream as hits at RMB 200-400. In 2025, facing a crowded retinol field and tighter claim rules, it shifted toward retinol-peptide combinations and gentler anti-aging; C2CC reports its parent is now in the IPO process.
Hero Products
Three-Year Financials
Neither the brand nor its parent publishes audited annual financials; no estimates are provided.
Brand-level：C2CC reports parent revenue in the RMB 2-5bn range without year-by-year figures.
Source：C2CC Media (Apr 2026); brand information
Company Coverage
- 2026-04Parent enters IPO process
C2CC reports HBN's parent is pursuing a listing with revenue in the RMB 2-5bn range.
Source：C2CC Media - 2025-12Retinol enters a regulated phase
With claims tightening, the brand refocuses on human efficacy evaluation and clinical data.
Source：Trade media - 2025-08Sensitive-skin anti-aging line
Low-dose retinol with peptides targets users who want anti-aging but fear irritation.
Source：Brand
Observation: HBN's moat is not just formulation but turning 'morning C, night A' into an executable routine — a successful act of category education. Yet retinol claims face stricter regulatory scrutiny, and without sufficient human efficacy data the old marketing language will not hold. Moving to retinol-peptide combinations is a pragmatic response.